109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
阿布昔替尼治疗头颈部皮炎：病例系列及文献综述
Authors Liu C, Pan Y , Xiong J, Saputra AD, Chen S, Cai T
Received 18 July 2025
Accepted for publication 4 November 2025
Published 20 November 2025 Volume 2025:18 Pages 3093—3102
DOI https://doi.org/10.2147/CCID.S549045
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Rungsima Wanitphakdeedecha
Chuan Liu, Yu Pan, Jianxia Xiong, Aldi Dayu Saputra, Shuang Chen, Tao Cai
Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China
Correspondence: Shuang Chen, Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing, 400000, People’s Republic of China, Email shuangchen07@hotmail.com Tao Cai, Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing, 400000, People’s Republic of China, Email caidaodao@hotmail.com
Background: Head and neck dermatitis (HND) is a recalcitrant subtype of atopic dermatitis (AD). Despite conventional therapies, including topical corticosteroids, calcineurin inhibitors, and biologics such as dupilumab, many patients remain refractory to treatment. Janus kinase (JAK) inhibitors, such as abrocitinib, offer a novel therapeutic approach targeting multiple inflammatory pathways implicated in HND.
Purpose: To evaluate the efficacy of abrocitinib in refractory HND and compare its effectiveness with other JAK inhibitors (upadacitinib, baricitinib).
Patients and Methods: We retrospectively analyzed three patients with HND treated with abrocitinib (100– 200 mg/day). Treatment response was assessed using Eczema Area and Severity Index (EASI) scores and the Investigator’s Global Assessment (IGA) of the head and neck. A PubMed literature review was conducted to compare abrocitinib with other JAK inhibitors in HND.
Results: All three abrocitinib-treated patients achieved rapid skin lesion relief within 1– 2 weeks and near-complete lesion clearance by Week 8. These results are consistent with clinical trial data highlighting the strong early efficacy of JAK inhibitors for head and neck lesions. While abrocitinib and upadacitinib demonstrated robust clinical responses, baricitinib showed comparatively weaker efficacy in the head and neck.
Conclusion: JAK inhibitors, particularly abrocitinib and upadacitinib, may be considered as first-line therapies for refractory HND. They offer both rapid symptom relief and sustained efficacy.
Keywords: head and neck dermatitis, atopic dermatitis, abrocitinib, JAK inhibitors
Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China
Correspondence: Shuang Chen, Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing, 400000, People’s Republic of China, Email shuangchen07@hotmail.com Tao Cai, Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing, 400000, People’s Republic of China, Email caidaodao@hotmail.com
Background: Head and neck dermatitis (HND) is a recalcitrant subtype of atopic dermatitis (AD). Despite conventional therapies, including topical corticosteroids, calcineurin inhibitors, and biologics such as dupilumab, many patients remain refractory to treatment. Janus kinase (JAK) inhibitors, such as abrocitinib, offer a novel therapeutic approach targeting multiple inflammatory pathways implicated in HND.
Purpose: To evaluate the efficacy of abrocitinib in refractory HND and compare its effectiveness with other JAK inhibitors (upadacitinib, baricitinib).
Patients and Methods: We retrospectively analyzed three patients with HND treated with abrocitinib (100– 200 mg/day). Treatment response was assessed using Eczema Area and Severity Index (EASI) scores and the Investigator’s Global Assessment (IGA) of the head and neck. A PubMed literature review was conducted to compare abrocitinib with other JAK inhibitors in HND.
Results: All three abrocitinib-treated patients achieved rapid skin lesion relief within 1– 2 weeks and near-complete lesion clearance by Week 8. These results are consistent with clinical trial data highlighting the strong early efficacy of JAK inhibitors for head and neck lesions. While abrocitinib and upadacitinib demonstrated robust clinical responses, baricitinib showed comparatively weaker efficacy in the head and neck.
Conclusion: JAK inhibitors, particularly abrocitinib and upadacitinib, may be considered as first-line therapies for refractory HND. They offer both rapid symptom relief and sustained efficacy.
Keywords: head and neck dermatitis, atopic dermatitis, abrocitinib, JAK inhibitors